

Supplemental Information

SUPPLEMENTAL TABLE 3 Estimated 1-Dose and 2-Dose VE Estimates Against Notified Rotavirus in Children Aged 6 Months to 9 Years, New South Wales (2010–2017)

Cohort	Case Patients	Controls	VE (95% CI)
2017			
All ages (6 mo–9 y), <i>n</i>	1031	10 300	
Unvaccinated, <i>n</i> (%)	295 (28.6)	697 (6.8)	Reference
1-dose vaccinated, <i>n</i> (%)	44 (4.3)	593 (5.8)	83.0 (76.2 to 87.9)
2-dose vaccinated, <i>n</i> (%)	692 (67.1)	9010 (87.5)	82.5 (79.4 to 85.1)
Aged 6–11 mo, <i>n</i>	91	900	
Unvaccinated, <i>n</i> (%)	26 (28.6)	44 (4.9)	Reference
1-dose vaccinated, <i>n</i> (%)	5 (5.5)	40 (4.4)	80.3 (43.1 to 93.2)
2-dose vaccinated, <i>n</i> (%)	60 (65.9)	816 (90.7)	88.4 (79.2 to 93.5)
Aged 1–3 y, <i>n</i>	625	6254	
Unvaccinated, <i>n</i> (%)	161 (26.9)	331 (5.3)	Reference
1-dose vaccinated, <i>n</i> (%)	26 (4.2)	360 (5.8)	84.9 (76.6 to 90.3)
2-dose vaccinated, <i>n</i> (%)	438 (70.1)	5563 (89.0)	83.7 (79.8 to 86.8)
Aged 4–9 y, <i>n</i>	315	3146	
Unvaccinated, <i>n</i> (%)	108 (34.3)	322 (10.2)	Reference
1-dose vaccinated, <i>n</i> (%)	13 (4.1)	193 (6.1)	80.7 (64.5 to 89.5)
2-dose vaccinated, <i>n</i> (%)	194 (61.6)	2631 (83.6)	78.7 (72.1 to 83.7)
2016			
All ages (6 mo–8 y), <i>n</i>	282	2820	
Unvaccinated, <i>n</i> (%)	81 (28.7)	204 (7.2)	Reference
1-dose vaccinated, <i>n</i> (%)	20 (7.1)	185 (6.6)	73.2 (54.5 to 84.3)
2-dose vaccinated, <i>n</i> (%)	181 (64.2)	2431 (86.2)	82.4 (76.0 to 87.1)
Aged 6–11 mo, <i>n</i>	42	420	
Unvaccinated, <i>n</i> (%)	17 (40.5)	22 (5.2)	Reference
1-dose vaccinated, <i>n</i> (%)	4 (9.5)	30 (7.1)	84.0 (42.6 to 95.6)
2-dose vaccinated, <i>n</i> (%)	21 (50.0)	368 (87.6)	92.5 (83.1 to 96.7)
Aged 1–3 y, <i>n</i>	164	1640	
Unvaccinated, <i>n</i> (%)	41 (25.0)	90 (5.5)	Reference
1-dose vaccinated, <i>n</i> (%)	12 (7.3)	104 (6.3)	72.9 (46.1 to 86.4)
2-dose vaccinated, <i>n</i> (%)	111 (67.7)	1446 (88.2)	83.5 (74.8 to 89.2)
Aged 4–8 y, <i>n</i>	76	760	
Unvaccinated, <i>n</i> (%)	23 (30.3)	92 (12.1)	Reference
1-dose vaccinated, <i>n</i> (%)	4 (5.3)	51 (6.7)	69.8 (7.4 to 90.2)
2-dose vaccinated, <i>n</i> (%)	49 (64.5)	617 (81.2)	69.9 (47.3 to 82.8)
2015			
All ages (6 mo–7 y), <i>n</i>	529	5285	
Unvaccinated, <i>n</i> (%)	95 (18.0)	432 (8.2)	Reference
1-dose vaccinated, <i>n</i> (%)	38 (7.2)	315 (6.0)	46.6 (19.6 to 64.5)
2-dose vaccinated, <i>n</i> (%)	396 (74.9)	4538 (85.9)	61.1 (50.2 to 69.7)
Aged 6–11 mo, <i>n</i>	43	425	
Unvaccinated, <i>n</i> (%)	7 (16.3)	23 (5.4)	Reference
1-dose vaccinated, <i>n</i> (%)	6 (14.0)	33 (7.8)	45.7 (–94.1 to 84.8) ^a
2-dose vaccinated, <i>n</i> (%)	30 (69.8)	369 (86.6)	74.7 (33.6 to 90.3)
Aged 1–3 y, <i>n</i>	361	3610	
Unvaccinated, <i>n</i> (%)	59 (16.3)	264 (7.3)	Reference
1-dose vaccinated, <i>n</i> (%)	25 (6.9)	200 (5.5)	44.6 (7.9 to 66.7)
2-dose vaccinated, <i>n</i> (%)	277 (76.7)	3146 (87.1)	60.9 (46.7 to 71.3)
Aged 4–7 y, <i>n</i>	125	1250	
Unvaccinated, <i>n</i> (%)	29 (23.2)	145 (11.6)	Reference
1-dose vaccinated, <i>n</i> (%)	7 (5.6)	82 (6.6)	58.3 (0.1 to 82.6)
2-dose vaccinated, <i>n</i> (%)	89 (71.2)	1023 (81.8)	57.4 (32.5 to 73.1)
2014			
All ages (6 mo–6 y), <i>n</i>	322	3215	
Unvaccinated, <i>n</i> (%)	84 (26.1)	282 (8.8)	Reference
1-dose vaccinated, <i>n</i> (%)	19 (5.9)	213 (6.6)	70.5 (49.7 to 82.7)
2-dose vaccinated, <i>n</i> (%)	219 (68.0)	2720 (84.6)	73.2 (64.4 to 79.8)
Aged 6–11 mo, <i>n</i>	37	371	
Unvaccinated, <i>n</i> (%)	10 (27.0)	23 (6.2)	Reference
1-dose vaccinated, <i>n</i> (%)	3 (8.1)	35 (9.4)	78.5 (13.9 to 94.6)
2-dose vaccinated, <i>n</i> (%)	24 (64.9)	313 (84.4)	80.3 (55.6 to 91.3)

SUPPLEMENTAL TABLE 3 Continued

Cohort	Case Patients	Controls	VE (95% CI)
Aged 1–3 y, <i>n</i>	230	2294	
Unvaccinated, <i>n</i> (%)	58 (25.2)	198 (8.6)	Reference
1-dose vaccinated, <i>n</i> (%)	14 (6.1)	150 (6.5)	68.4 (41.0 to 83.1)
2-dose vaccinated, <i>n</i> (%)	158 (68.7)	1946 (84.8)	72.7 (61.7 to 80.6)
Aged 4–6 y, <i>n</i>	55	550	
Unvaccinated, <i>n</i> (%)	16 (29.1)	61 (11.1)	Reference
1-dose vaccinated, <i>n</i> (%)	2 (3.6)	28 (5.1)	73.8 (–23.8 to 94.5) ^a
2-dose vaccinated, <i>n</i> (%)	37 (67.3)	461 (83.8)	68.9 (40.9 to 83.6)
2013			
All ages (6 mo–5 y), <i>n</i>	159	1580	
Unvaccinated, <i>n</i> (%)	40 (25.2)	176 (11.1)	Reference
1-dose vaccinated, <i>n</i> (%)	5 (3.1)	97 (6.1)	77.3 (40.4 to 91.3)
2-dose vaccinated, <i>n</i> (%)	114 (71.7)	1307 (82.7)	62.0 (43.6 to 74.4)
Aged 6–11 mo, <i>n</i>	29	280	
Unvaccinated, <i>n</i> (%)	9 (31.0)	29 (10.4)	Reference
1-dose vaccinated, <i>n</i> (%)	0 (0.0)	15 (5.4)	100.0 (0.0 to ∞) ^a
2-dose vaccinated, <i>n</i> (%)	20 (69.0)	236 (84.3)	74.5 (37.5 to 89.6)
Aged 1–3 y, <i>n</i>	104	1040	
Unvaccinated, <i>n</i> (%)	24 (23.1)	111 (10.7)	Reference
1-dose vaccinated, <i>n</i> (%)	5 (4.8)	66 (6.3)	65.2 (4.0 to 87.4)
2-dose vaccinated, <i>n</i> (%)	75 (72.1)	863 (83.0)	60.1 (34.1 to 75.9)
Aged 4–5 y, <i>n</i>	26	260	
Unvaccinated, <i>n</i> (%)	7 (26.9)	36 (13.8)	Reference
1-dose vaccinated, <i>n</i> (%)	0 (0.0)	16 (6.2)	N/A
2-dose vaccinated, <i>n</i> (%)	19 (73.1)	208 (80.0)	51.3 (–21.2 to 80.4) ^a
2012			
All ages (6 mo–4 y), <i>n</i>	586	5860	
Unvaccinated, <i>n</i> (%)	126 (21.5)	651 (11.1)	Reference
1-dose vaccinated, <i>n</i> (%)	53 (9.0)	386 (6.6)	29.5 (0.4 to 50.1)
2-dose vaccinated, <i>n</i> (%)	407 (69.5)	4823 (82.3)	56.7 (46.2 to 65.1)
Aged 6–11 mo, <i>n</i>	76	760	
Unvaccinated, <i>n</i> (%)	20 (26.3)	65 (8.6)	Reference
1-dose vaccinated, <i>n</i> (%)	8 (10.5)	47 (6.2)	45.2 (–36.7 to 78.0) ^a
2-dose vaccinated, <i>n</i> (%)	48 (63.2)	648 (85.3)	75.2 (55.8 to 86.1)
Aged 1–3 y, <i>n</i>	451	4510	
Unvaccinated, <i>n</i> (%)	93 (20.6)	509 (11.3)	Reference
1-dose vaccinated, <i>n</i> (%)	41 (9.1)	296 (6.6)	24.5 (–12.1 to 49.1) ^a
2-dose vaccinated, <i>n</i> (%)	317 (70.3)	3705 (82.2)	53.6 (40.3 to 63.9)
Aged 4 y, <i>n</i>	59	590	
Unvaccinated, <i>n</i> (%)	13 (22.0)	77 (13.1)	Reference
1-dose vaccinated, <i>n</i> (%)	4 (6.8)	43 (7.3)	45.0 (–77.6 to 83.0) ^a
2-dose vaccinated, <i>n</i> (%)	42 (71.2)	470 (79.7)	47.3 (–2.9 to 72.8) ^a
2011			
All ages (6 mo–3 y), <i>n</i>	367	3670	
Unvaccinated, <i>n</i> (%)	63 (17.2)	445 (12.1)	Reference
1-dose vaccinated, <i>n</i> (%)	21 (5.7)	238 (6.5)	37.8 (–4.8 to 63.1) ^a
2-dose vaccinated, <i>n</i> (%)	283 (77.1)	2987 (81.4)	33.1 (10.5 to 50.0)
Aged 6–11 mo, <i>n</i>	86	860	
Unvaccinated, <i>n</i> (%)	8 (9.3)	112 (13.0)	Reference
1-dose vaccinated, <i>n</i> (%)	5 (5.8)	63 (7.3)	–10.6 (–252.6 to 65.3) ^a
2-dose vaccinated, <i>n</i> (%)	73 (84.9)	685 (79.7)	–48.8 (–216.3 to 30.0) ^a
Aged 1–3 y, <i>n</i>	281	2810	
Unvaccinated, <i>n</i> (%)	55 (19.6)	333 (11.9)	Reference
1-dose vaccinated, <i>n</i> (%)	16 (5.7)	175 (6.2)	44.9 (0.4 to 69.5)
2-dose vaccinated, <i>n</i> (%)	210 (74.7)	2302 (81.9)	44.9 (24.1 to 59.9)
2010			
All ages (6 mo–2 y), <i>n</i>	311	3099	
Unvaccinated, <i>n</i> (%)	182 (58.5)	409 (13.2)	Reference
1-dose vaccinated, <i>n</i> (%)	14 (4.5)	194 (6.3)	84.7 (72.6 to 91.4)
2-dose vaccinated, <i>n</i> (%)	115 (37.0)	2496 (80.5)	89.7 (86.5 to 92.0)
Aged 6–11 mo, <i>n</i>	84	829	

SUPPLEMENTAL TABLE 3 Continued

Cohort	Case Patients	Controls	VE (95% CI)
Unvaccinated, <i>n</i> (%)	56 (66.7)	97 (11.7)	Reference
1-dose vaccinated, <i>n</i> (%)	5 (6.0)	53 (6.4)	87.4 (64.9 to 95.5)
2-dose vaccinated, <i>n</i> (%)	23 (27.4)	679 (81.9)	94.5 (90.4 to 96.9)
Aged 1–2 y, <i>n</i>	227	2270	
Unvaccinated, <i>n</i> (%)	126 (55.5)	312 (13.7)	Reference
1-dose vaccinated, <i>n</i> (%)	9 (4.0)	141 (6.2)	84.4 (68.1 to 92.3)
2-dose vaccinated, <i>n</i> (%)	92 (40.5)	1817 (80.0)	87.2 (82.8 to 90.5)

^a Not statistically significant ($P > .05$).